nodes	percent_of_prediction	percent_of_DWPC	metapath
Loxapine—CHRM3—muscle of abdomen—breast cancer	0.00938	0.121	CbGeAlD
Loxapine—HRH4—bone marrow—breast cancer	0.00349	0.0451	CbGeAlD
Loxapine—Trifluoperazine—S100A4—breast cancer	0.00244	0.22	CrCbGaD
Loxapine—CHRM5—epithelium—breast cancer	0.002	0.0258	CbGeAlD
Loxapine—HRH2—skin of body—breast cancer	0.00199	0.0256	CbGeAlD
Loxapine—HTR1E—female gonad—breast cancer	0.00197	0.0254	CbGeAlD
Loxapine—CHRM5—skin of body—breast cancer	0.0019	0.0245	CbGeAlD
Loxapine—DRD5—female reproductive system—breast cancer	0.00165	0.0213	CbGeAlD
Loxapine—HRH2—adrenal gland—breast cancer	0.00152	0.0195	CbGeAlD
Loxapine—DRD5—female gonad—breast cancer	0.00151	0.0194	CbGeAlD
Loxapine—ADRA2C—nipple—breast cancer	0.00145	0.0187	CbGeAlD
Loxapine—DRD5—endocrine gland—breast cancer	0.0014	0.0181	CbGeAlD
Loxapine—HRH2—endocrine gland—breast cancer	0.00131	0.017	CbGeAlD
Loxapine—HRH1—nipple—breast cancer	0.00118	0.0152	CbGeAlD
Loxapine—ADRA2A—nipple—breast cancer	0.00116	0.0149	CbGeAlD
Loxapine—HTR7—epithelium—breast cancer	0.00106	0.0137	CbGeAlD
Loxapine—ADRB1—adipose tissue—breast cancer	0.00105	0.0135	CbGeAlD
Loxapine—ADRA1A—epithelium—breast cancer	0.00103	0.0132	CbGeAlD
Loxapine—HTR1B—female reproductive system—breast cancer	0.00102	0.0132	CbGeAlD
Loxapine—HTR1D—female reproductive system—breast cancer	0.000991	0.0128	CbGeAlD
Loxapine—HTR2C—female reproductive system—breast cancer	0.000982	0.0127	CbGeAlD
Loxapine—ADRB1—female reproductive system—breast cancer	0.000963	0.0124	CbGeAlD
Loxapine—SLC6A4—female reproductive system—breast cancer	0.000931	0.012	CbGeAlD
Loxapine—CHRM1—female reproductive system—breast cancer	0.000927	0.012	CbGeAlD
Loxapine—HRH2—lymph node—breast cancer	0.000909	0.0117	CbGeAlD
Loxapine—CHRM3—adipose tissue—breast cancer	0.000903	0.0116	CbGeAlD
Loxapine—ADRA2C—endometrium—breast cancer	0.000876	0.0113	CbGeAlD
Loxapine—HTR1B—endocrine gland—breast cancer	0.000867	0.0112	CbGeAlD
Loxapine—CHRM2—endocrine gland—breast cancer	0.000862	0.0111	CbGeAlD
Loxapine—HTR6—Raloxifene—breast cancer	0.000844	1	CbGbCtD
Loxapine—CHRM3—female reproductive system—breast cancer	0.00083	0.0107	CbGeAlD
Loxapine—ADRA1A—adipose tissue—breast cancer	0.000829	0.0107	CbGeAlD
Loxapine—SLC6A2—female reproductive system—breast cancer	0.000819	0.0106	CbGeAlD
Loxapine—DRD2—pituitary gland—breast cancer	0.000816	0.0105	CbGeAlD
Loxapine—ADRB1—endocrine gland—breast cancer	0.000815	0.0105	CbGeAlD
Loxapine—HTR2A—embryo—breast cancer	0.000812	0.0105	CbGeAlD
Loxapine—ADRA2C—uterus—breast cancer	0.000807	0.0104	CbGeAlD
Loxapine—HTR1A—adrenal gland—breast cancer	0.000806	0.0104	CbGeAlD
Loxapine—SLC6A2—adrenal gland—breast cancer	0.0008	0.0103	CbGeAlD
Loxapine—HRH1—epithelium—breast cancer	0.000794	0.0102	CbGeAlD
Loxapine—ADRA2C—pituitary gland—breast cancer	0.000793	0.0102	CbGeAlD
Loxapine—HTR7—female reproductive system—breast cancer	0.00079	0.0102	CbGeAlD
Loxapine—ADRA2C—adipose tissue—breast cancer	0.00079	0.0102	CbGeAlD
Loxapine—SLC6A4—endocrine gland—breast cancer	0.000788	0.0102	CbGeAlD
Loxapine—CHRM1—endocrine gland—breast cancer	0.000785	0.0101	CbGeAlD
Loxapine—HTR7—adrenal gland—breast cancer	0.000771	0.00994	CbGeAlD
Loxapine—CHRM3—female gonad—breast cancer	0.000755	0.00974	CbGeAlD
Loxapine—ADRA1A—adrenal gland—breast cancer	0.000743	0.00959	CbGeAlD
Loxapine—HRH1—endometrium—breast cancer	0.000712	0.00918	CbGeAlD
Loxapine—ADRA2C—adrenal gland—breast cancer	0.000708	0.00914	CbGeAlD
Loxapine—CHRM3—endocrine gland—breast cancer	0.000702	0.00905	CbGeAlD
Loxapine—HTR1A—endocrine gland—breast cancer	0.000699	0.00902	CbGeAlD
Loxapine—ADRA2A—endometrium—breast cancer	0.000699	0.00902	CbGeAlD
Loxapine—SLC6A2—endocrine gland—breast cancer	0.000693	0.00894	CbGeAlD
Loxapine—HTR7—endocrine gland—breast cancer	0.000668	0.00862	CbGeAlD
Loxapine—HTR2A—epithelium—breast cancer	0.000663	0.00855	CbGeAlD
Loxapine—ADRA2C—female gonad—breast cancer	0.000661	0.00852	CbGeAlD
Loxapine—ADRA1A—endocrine gland—breast cancer	0.000645	0.00831	CbGeAlD
Loxapine—ADRA2A—uterus—breast cancer	0.000644	0.00831	CbGeAlD
Loxapine—HRH1—adipose tissue—breast cancer	0.000642	0.00827	CbGeAlD
Loxapine—ADRA2A—pituitary gland—breast cancer	0.000633	0.00816	CbGeAlD
Loxapine—DRD2—endocrine gland—breast cancer	0.000632	0.00815	CbGeAlD
Loxapine—ADRA2A—adipose tissue—breast cancer	0.00063	0.00813	CbGeAlD
Loxapine—HRH1—female reproductive system—breast cancer	0.00059	0.0076	CbGeAlD
Loxapine—ADRA2A—female reproductive system—breast cancer	0.000579	0.00747	CbGeAlD
Loxapine—HRH1—adrenal gland—breast cancer	0.000575	0.00742	CbGeAlD
Loxapine—ADRA2A—adrenal gland—breast cancer	0.000565	0.00729	CbGeAlD
Loxapine—HTR2A—pituitary gland—breast cancer	0.000538	0.00694	CbGeAlD
Loxapine—HRH1—female gonad—breast cancer	0.000537	0.00692	CbGeAlD
Loxapine—ADRA2A—female gonad—breast cancer	0.000527	0.0068	CbGeAlD
Loxapine—Azatadine—CYP3A4—breast cancer	0.000519	0.0468	CrCbGaD
Loxapine—HRH1—endocrine gland—breast cancer	0.000499	0.00644	CbGeAlD
Loxapine—HTR2A—female reproductive system—breast cancer	0.000493	0.00635	CbGeAlD
Loxapine—ADRA2A—endocrine gland—breast cancer	0.00049	0.00632	CbGeAlD
Loxapine—HTR2A—adrenal gland—breast cancer	0.000481	0.0062	CbGeAlD
Loxapine—SLC6A2—lymph node—breast cancer	0.000479	0.00618	CbGeAlD
Loxapine—Asenapine—CYP2D6—breast cancer	0.000465	0.0419	CrCbGaD
Loxapine—ADRA2C—lymph node—breast cancer	0.000425	0.00548	CbGeAlD
Loxapine—HTR2A—endocrine gland—breast cancer	0.000417	0.00537	CbGeAlD
Loxapine—Azelastine—CYP1A1—breast cancer	0.000405	0.0365	CrCbGaD
Loxapine—Asenapine—CYP3A4—breast cancer	0.000399	0.036	CrCbGaD
Loxapine—HRH1—lymph node—breast cancer	0.000345	0.00445	CbGeAlD
Loxapine—ADRA2A—lymph node—breast cancer	0.000339	0.00437	CbGeAlD
Loxapine—Clozapine—CYP1B1—breast cancer	0.000336	0.0303	CrCbGaD
Loxapine—Azelastine—CYP2D6—breast cancer	0.000301	0.0272	CrCbGaD
Loxapine—Chlordiazepoxide—CYP2D6—breast cancer	0.000277	0.0249	CrCbGaD
Loxapine—Zuclopenthixol—CYP2D6—breast cancer	0.000272	0.0245	CrCbGaD
Loxapine—Dizziness—Thiotepa—breast cancer	0.000264	0.000521	CcSEcCtD
Loxapine—Rash—Vinorelbine—breast cancer	0.000264	0.00052	CcSEcCtD
Loxapine—Dermatitis—Vinorelbine—breast cancer	0.000263	0.000519	CcSEcCtD
Loxapine—Hypotension—Paclitaxel—breast cancer	0.000263	0.000518	CcSEcCtD
Loxapine—Headache—Vinorelbine—breast cancer	0.000262	0.000516	CcSEcCtD
Loxapine—Syncope—Docetaxel—breast cancer	0.000262	0.000516	CcSEcCtD
Loxapine—Dysphagia—Doxorubicin—breast cancer	0.000262	0.000516	CcSEcCtD
Loxapine—Leukopenia—Docetaxel—breast cancer	0.000262	0.000515	CcSEcCtD
Loxapine—Olanzapine—CYP2D6—breast cancer	0.000259	0.0233	CrCbGaD
Loxapine—Azelastine—CYP3A4—breast cancer	0.000258	0.0233	CrCbGaD
Loxapine—Photosensitivity reaction—Epirubicin—breast cancer	0.000258	0.000509	CcSEcCtD
Loxapine—Weight increased—Epirubicin—breast cancer	0.000257	0.000507	CcSEcCtD
Loxapine—Loss of consciousness—Docetaxel—breast cancer	0.000257	0.000506	CcSEcCtD
Loxapine—Weight decreased—Epirubicin—breast cancer	0.000256	0.000504	CcSEcCtD
Loxapine—Cough—Docetaxel—breast cancer	0.000255	0.000502	CcSEcCtD
Loxapine—Insomnia—Paclitaxel—breast cancer	0.000254	0.000501	CcSEcCtD
Loxapine—Hypersensitivity—Mitoxantrone—breast cancer	0.000254	0.000501	CcSEcCtD
Loxapine—Hypersensitivity—Irinotecan—breast cancer	0.000254	0.000501	CcSEcCtD
Loxapine—Vomiting—Thiotepa—breast cancer	0.000254	0.000501	CcSEcCtD
Loxapine—Syncope—Capecitabine—breast cancer	0.000254	0.0005	CcSEcCtD
Loxapine—Leukopenia—Capecitabine—breast cancer	0.000253	0.000499	CcSEcCtD
Loxapine—Convulsion—Docetaxel—breast cancer	0.000253	0.000499	CcSEcCtD
Loxapine—Paraesthesia—Paclitaxel—breast cancer	0.000253	0.000498	CcSEcCtD
Loxapine—Hypertension—Docetaxel—breast cancer	0.000252	0.000497	CcSEcCtD
Loxapine—Drowsiness—Epirubicin—breast cancer	0.000252	0.000497	CcSEcCtD
Loxapine—Rash—Thiotepa—breast cancer	0.000252	0.000496	CcSEcCtD
Loxapine—Dermatitis—Thiotepa—breast cancer	0.000252	0.000496	CcSEcCtD
Loxapine—Agranulocytosis—Methotrexate—breast cancer	0.000251	0.000496	CcSEcCtD
Loxapine—Dyspnoea—Paclitaxel—breast cancer	0.000251	0.000494	CcSEcCtD
Loxapine—Headache—Thiotepa—breast cancer	0.00025	0.000493	CcSEcCtD
Loxapine—Somnolence—Paclitaxel—breast cancer	0.00025	0.000493	CcSEcCtD
Loxapine—Trazodone—CYP2D6—breast cancer	0.00025	0.0225	CrCbGaD
Loxapine—Chest pain—Docetaxel—breast cancer	0.000249	0.00049	CcSEcCtD
Loxapine—Loss of consciousness—Capecitabine—breast cancer	0.000249	0.00049	CcSEcCtD
Loxapine—Nausea—Vinorelbine—breast cancer	0.000248	0.00049	CcSEcCtD
Loxapine—Renal failure—Epirubicin—breast cancer	0.000248	0.000489	CcSEcCtD
Loxapine—Asthenia—Mitoxantrone—breast cancer	0.000248	0.000488	CcSEcCtD
Loxapine—Asthenia—Irinotecan—breast cancer	0.000248	0.000488	CcSEcCtD
Loxapine—Cough—Capecitabine—breast cancer	0.000247	0.000487	CcSEcCtD
Loxapine—Jaundice—Epirubicin—breast cancer	0.000246	0.000484	CcSEcCtD
Loxapine—Hypertension—Capecitabine—breast cancer	0.000244	0.000481	CcSEcCtD
Loxapine—Hypersensitivity—Fluorouracil—breast cancer	0.000243	0.00048	CcSEcCtD
Loxapine—Dry mouth—Docetaxel—breast cancer	0.000243	0.000479	CcSEcCtD
Loxapine—Gastrointestinal disorder—Paclitaxel—breast cancer	0.000243	0.000479	CcSEcCtD
Loxapine—Fatigue—Paclitaxel—breast cancer	0.000243	0.000478	CcSEcCtD
Loxapine—Hepatitis—Methotrexate—breast cancer	0.000242	0.000477	CcSEcCtD
Loxapine—Asthenia—Gemcitabine—breast cancer	0.000241	0.000475	CcSEcCtD
Loxapine—Chest pain—Capecitabine—breast cancer	0.000241	0.000475	CcSEcCtD
Loxapine—Constipation—Paclitaxel—breast cancer	0.000241	0.000474	CcSEcCtD
Loxapine—Confusional state—Docetaxel—breast cancer	0.00024	0.000474	CcSEcCtD
Loxapine—Photosensitivity reaction—Doxorubicin—breast cancer	0.000239	0.000471	CcSEcCtD
Loxapine—Oedema—Docetaxel—breast cancer	0.000238	0.00047	CcSEcCtD
Loxapine—Weight increased—Doxorubicin—breast cancer	0.000238	0.000469	CcSEcCtD
Loxapine—Pruritus—Gemcitabine—breast cancer	0.000238	0.000469	CcSEcCtD
Loxapine—Chlordiazepoxide—CYP3A4—breast cancer	0.000237	0.0214	CrCbGaD
Loxapine—Nausea—Thiotepa—breast cancer	0.000237	0.000468	CcSEcCtD
Loxapine—Weight decreased—Doxorubicin—breast cancer	0.000237	0.000467	CcSEcCtD
Loxapine—Dry mouth—Capecitabine—breast cancer	0.000236	0.000464	CcSEcCtD
Loxapine—Agranulocytosis—Epirubicin—breast cancer	0.000235	0.000464	CcSEcCtD
Loxapine—Shock—Docetaxel—breast cancer	0.000235	0.000462	CcSEcCtD
Loxapine—Thiothixene—CYP2D6—breast cancer	0.000234	0.0211	CrCbGaD
Loxapine—Nervous system disorder—Docetaxel—breast cancer	0.000234	0.000461	CcSEcCtD
Loxapine—Pruritus—Fluorouracil—breast cancer	0.000234	0.000461	CcSEcCtD
Loxapine—Thrombocytopenia—Docetaxel—breast cancer	0.000233	0.00046	CcSEcCtD
Loxapine—Drowsiness—Doxorubicin—breast cancer	0.000233	0.00046	CcSEcCtD
Loxapine—Confusional state—Capecitabine—breast cancer	0.000233	0.000459	CcSEcCtD
Loxapine—Tachycardia—Docetaxel—breast cancer	0.000233	0.000459	CcSEcCtD
Loxapine—Feeling abnormal—Paclitaxel—breast cancer	0.000232	0.000457	CcSEcCtD
Loxapine—Oedema—Capecitabine—breast cancer	0.000231	0.000455	CcSEcCtD
Loxapine—Renal failure—Doxorubicin—breast cancer	0.000229	0.000452	CcSEcCtD
Loxapine—Dizziness—Irinotecan—breast cancer	0.000228	0.00045	CcSEcCtD
Loxapine—Jaundice—Doxorubicin—breast cancer	0.000227	0.000448	CcSEcCtD
Loxapine—Shock—Capecitabine—breast cancer	0.000227	0.000448	CcSEcCtD
Loxapine—Nervous system disorder—Capecitabine—breast cancer	0.000226	0.000446	CcSEcCtD
Loxapine—Hepatitis—Epirubicin—breast cancer	0.000226	0.000446	CcSEcCtD
Loxapine—Thrombocytopenia—Capecitabine—breast cancer	0.000226	0.000446	CcSEcCtD
Loxapine—Tachycardia—Capecitabine—breast cancer	0.000225	0.000444	CcSEcCtD
Loxapine—Hypoaesthesia—Epirubicin—breast cancer	0.000225	0.000444	CcSEcCtD
Loxapine—Prochlorperazine—CYP2D6—breast cancer	0.000224	0.0202	CrCbGaD
Loxapine—Hypotension—Docetaxel—breast cancer	0.000223	0.000439	CcSEcCtD
Loxapine—Olanzapine—CYP3A4—breast cancer	0.000222	0.02	CrCbGaD
Loxapine—Angiopathy—Methotrexate—breast cancer	0.000219	0.000433	CcSEcCtD
Loxapine—Vomiting—Mitoxantrone—breast cancer	0.000219	0.000432	CcSEcCtD
Loxapine—Vomiting—Irinotecan—breast cancer	0.000219	0.000432	CcSEcCtD
Loxapine—Dizziness—Fluorouracil—breast cancer	0.000218	0.000431	CcSEcCtD
Loxapine—Mediastinal disorder—Methotrexate—breast cancer	0.000218	0.00043	CcSEcCtD
Loxapine—Agranulocytosis—Doxorubicin—breast cancer	0.000218	0.000429	CcSEcCtD
Loxapine—Rash—Irinotecan—breast cancer	0.000218	0.000429	CcSEcCtD
Loxapine—Rash—Mitoxantrone—breast cancer	0.000218	0.000429	CcSEcCtD
Loxapine—Dermatitis—Mitoxantrone—breast cancer	0.000217	0.000428	CcSEcCtD
Loxapine—Dermatitis—Irinotecan—breast cancer	0.000217	0.000428	CcSEcCtD
Loxapine—Headache—Mitoxantrone—breast cancer	0.000216	0.000426	CcSEcCtD
Loxapine—Headache—Irinotecan—breast cancer	0.000216	0.000426	CcSEcCtD
Loxapine—Hypotension—Capecitabine—breast cancer	0.000216	0.000425	CcSEcCtD
Loxapine—Insomnia—Docetaxel—breast cancer	0.000216	0.000425	CcSEcCtD
Loxapine—Azelastine—ABCB1—breast cancer	0.000215	0.0194	CrCbGaD
Loxapine—Trazodone—CYP3A4—breast cancer	0.000215	0.0193	CrCbGaD
Loxapine—Paraesthesia—Docetaxel—breast cancer	0.000214	0.000422	CcSEcCtD
Loxapine—Alopecia—Methotrexate—breast cancer	0.000214	0.000421	CcSEcCtD
Loxapine—Vomiting—Gemcitabine—breast cancer	0.000214	0.000421	CcSEcCtD
Loxapine—Dyspnoea—Docetaxel—breast cancer	0.000213	0.000419	CcSEcCtD
Loxapine—Somnolence—Docetaxel—breast cancer	0.000212	0.000418	CcSEcCtD
Loxapine—Rash—Gemcitabine—breast cancer	0.000212	0.000418	CcSEcCtD
Loxapine—Dermatitis—Gemcitabine—breast cancer	0.000212	0.000417	CcSEcCtD
Loxapine—Headache—Gemcitabine—breast cancer	0.000211	0.000415	CcSEcCtD
Loxapine—Vomiting—Fluorouracil—breast cancer	0.00021	0.000414	CcSEcCtD
Loxapine—Hepatitis—Doxorubicin—breast cancer	0.000209	0.000413	CcSEcCtD
Loxapine—Insomnia—Capecitabine—breast cancer	0.000209	0.000412	CcSEcCtD
Loxapine—Hypoaesthesia—Doxorubicin—breast cancer	0.000208	0.000411	CcSEcCtD
Loxapine—Rash—Fluorouracil—breast cancer	0.000208	0.000411	CcSEcCtD
Loxapine—Dermatitis—Fluorouracil—breast cancer	0.000208	0.00041	CcSEcCtD
Loxapine—Paraesthesia—Capecitabine—breast cancer	0.000207	0.000409	CcSEcCtD
Loxapine—Hypersensitivity—Paclitaxel—breast cancer	0.000207	0.000409	CcSEcCtD
Loxapine—Headache—Fluorouracil—breast cancer	0.000207	0.000408	CcSEcCtD
Loxapine—Dysgeusia—Methotrexate—breast cancer	0.000206	0.000406	CcSEcCtD
Loxapine—Amoxapine—CYP2D6—breast cancer	0.000206	0.0186	CrCbGaD
Loxapine—Gastrointestinal disorder—Docetaxel—breast cancer	0.000206	0.000406	CcSEcCtD
Loxapine—Dyspnoea—Capecitabine—breast cancer	0.000206	0.000406	CcSEcCtD
Loxapine—Fatigue—Docetaxel—breast cancer	0.000206	0.000405	CcSEcCtD
Loxapine—Angiopathy—Epirubicin—breast cancer	0.000205	0.000405	CcSEcCtD
Loxapine—Nausea—Mitoxantrone—breast cancer	0.000205	0.000404	CcSEcCtD
Loxapine—Nausea—Irinotecan—breast cancer	0.000205	0.000404	CcSEcCtD
Loxapine—Mediastinal disorder—Epirubicin—breast cancer	0.000204	0.000402	CcSEcCtD
Loxapine—Constipation—Docetaxel—breast cancer	0.000204	0.000402	CcSEcCtD
Loxapine—Asthenia—Paclitaxel—breast cancer	0.000202	0.000398	CcSEcCtD
Loxapine—Clobazam—CYP3A4—breast cancer	0.000201	0.0181	CrCbGaD
Loxapine—Alprazolam—CYP3A4—breast cancer	0.000201	0.0181	CrCbGaD
Loxapine—Diazepam—PTGS1—breast cancer	0.000201	0.0181	CrCbGaD
Loxapine—Alopecia—Epirubicin—breast cancer	0.0002	0.000394	CcSEcCtD
Loxapine—Nausea—Gemcitabine—breast cancer	0.0002	0.000393	CcSEcCtD
Loxapine—Gastrointestinal disorder—Capecitabine—breast cancer	0.000199	0.000393	CcSEcCtD
Loxapine—Fatigue—Capecitabine—breast cancer	0.000199	0.000392	CcSEcCtD
Loxapine—Pruritus—Paclitaxel—breast cancer	0.000199	0.000392	CcSEcCtD
Loxapine—Vision blurred—Methotrexate—breast cancer	0.000198	0.000391	CcSEcCtD
Loxapine—Constipation—Capecitabine—breast cancer	0.000197	0.000389	CcSEcCtD
Loxapine—Feeling abnormal—Docetaxel—breast cancer	0.000197	0.000387	CcSEcCtD
Loxapine—Nausea—Fluorouracil—breast cancer	0.000196	0.000387	CcSEcCtD
Loxapine—Olanzapine—ALB—breast cancer	0.000194	0.0175	CrCbGaD
Loxapine—Tension—Epirubicin—breast cancer	0.000193	0.000381	CcSEcCtD
Loxapine—Dysgeusia—Epirubicin—breast cancer	0.000193	0.00038	CcSEcCtD
Loxapine—Prochlorperazine—CYP3A4—breast cancer	0.000192	0.0173	CrCbGaD
Loxapine—Feeling abnormal—Capecitabine—breast cancer	0.00019	0.000375	CcSEcCtD
Loxapine—Angiopathy—Doxorubicin—breast cancer	0.00019	0.000375	CcSEcCtD
Loxapine—Muscle spasms—Epirubicin—breast cancer	0.000189	0.000373	CcSEcCtD
Loxapine—Mediastinal disorder—Doxorubicin—breast cancer	0.000189	0.000372	CcSEcCtD
Loxapine—Leukopenia—Methotrexate—breast cancer	0.000189	0.000372	CcSEcCtD
Loxapine—Dizziness—Paclitaxel—breast cancer	0.000186	0.000367	CcSEcCtD
Loxapine—Vision blurred—Epirubicin—breast cancer	0.000186	0.000366	CcSEcCtD
Loxapine—Alopecia—Doxorubicin—breast cancer	0.000185	0.000365	CcSEcCtD
Loxapine—Olanzapine—ABCB1—breast cancer	0.000185	0.0167	CrCbGaD
Loxapine—Cough—Methotrexate—breast cancer	0.000184	0.000362	CcSEcCtD
Loxapine—Convulsion—Methotrexate—breast cancer	0.000182	0.00036	CcSEcCtD
Loxapine—Clozapine—CYP1A1—breast cancer	0.000182	0.0164	CrCbGaD
Loxapine—Agitation—Epirubicin—breast cancer	0.000181	0.000357	CcSEcCtD
Loxapine—Chest pain—Methotrexate—breast cancer	0.000179	0.000353	CcSEcCtD
Loxapine—Tension—Doxorubicin—breast cancer	0.000179	0.000353	CcSEcCtD
Loxapine—Vomiting—Paclitaxel—breast cancer	0.000179	0.000353	CcSEcCtD
Loxapine—Trazodone—ABCB1—breast cancer	0.000179	0.0161	CrCbGaD
Loxapine—Dysgeusia—Doxorubicin—breast cancer	0.000179	0.000352	CcSEcCtD
Loxapine—Rash—Paclitaxel—breast cancer	0.000177	0.00035	CcSEcCtD
Loxapine—Dermatitis—Paclitaxel—breast cancer	0.000177	0.000349	CcSEcCtD
Loxapine—Syncope—Epirubicin—breast cancer	0.000177	0.000348	CcSEcCtD
Loxapine—Leukopenia—Epirubicin—breast cancer	0.000176	0.000348	CcSEcCtD
Loxapine—Headache—Paclitaxel—breast cancer	0.000176	0.000347	CcSEcCtD
Loxapine—Hypersensitivity—Docetaxel—breast cancer	0.000176	0.000346	CcSEcCtD
Loxapine—Thiothixene—ALB—breast cancer	0.000175	0.0158	CrCbGaD
Loxapine—Muscle spasms—Doxorubicin—breast cancer	0.000175	0.000346	CcSEcCtD
Loxapine—Confusional state—Methotrexate—breast cancer	0.000173	0.000342	CcSEcCtD
Loxapine—Loss of consciousness—Epirubicin—breast cancer	0.000173	0.000341	CcSEcCtD
Loxapine—Cough—Epirubicin—breast cancer	0.000172	0.000339	CcSEcCtD
Loxapine—Vision blurred—Doxorubicin—breast cancer	0.000172	0.000339	CcSEcCtD
Loxapine—Asthenia—Docetaxel—breast cancer	0.000171	0.000337	CcSEcCtD
Loxapine—Convulsion—Epirubicin—breast cancer	0.000171	0.000337	CcSEcCtD
Loxapine—Hypertension—Epirubicin—breast cancer	0.00017	0.000335	CcSEcCtD
Loxapine—Hypersensitivity—Capecitabine—breast cancer	0.00017	0.000335	CcSEcCtD
Loxapine—Pruritus—Docetaxel—breast cancer	0.000169	0.000332	CcSEcCtD
Loxapine—Nervous system disorder—Methotrexate—breast cancer	0.000169	0.000332	CcSEcCtD
Loxapine—Thrombocytopenia—Methotrexate—breast cancer	0.000168	0.000332	CcSEcCtD
Loxapine—Chest pain—Epirubicin—breast cancer	0.000168	0.000331	CcSEcCtD
Loxapine—Agitation—Doxorubicin—breast cancer	0.000168	0.00033	CcSEcCtD
Loxapine—Clobazam—ABCB1—breast cancer	0.000167	0.0151	CrCbGaD
Loxapine—Nausea—Paclitaxel—breast cancer	0.000167	0.000329	CcSEcCtD
Loxapine—Asthenia—Capecitabine—breast cancer	0.000166	0.000326	CcSEcCtD
Loxapine—Dry mouth—Epirubicin—breast cancer	0.000164	0.000323	CcSEcCtD
Loxapine—Syncope—Doxorubicin—breast cancer	0.000164	0.000322	CcSEcCtD
Loxapine—Pruritus—Capecitabine—breast cancer	0.000163	0.000322	CcSEcCtD
Loxapine—Leukopenia—Doxorubicin—breast cancer	0.000163	0.000322	CcSEcCtD
Loxapine—Confusional state—Epirubicin—breast cancer	0.000162	0.00032	CcSEcCtD
Loxapine—Oedema—Epirubicin—breast cancer	0.000161	0.000317	CcSEcCtD
Loxapine—Hypotension—Methotrexate—breast cancer	0.000161	0.000317	CcSEcCtD
Loxapine—Loss of consciousness—Doxorubicin—breast cancer	0.00016	0.000316	CcSEcCtD
Loxapine—Cough—Doxorubicin—breast cancer	0.000159	0.000314	CcSEcCtD
Loxapine—Prazepam—CYP3A4—breast cancer	0.000158	0.0143	CrCbGaD
Loxapine—Shock—Epirubicin—breast cancer	0.000158	0.000312	CcSEcCtD
Loxapine—Convulsion—Doxorubicin—breast cancer	0.000158	0.000311	CcSEcCtD
Loxapine—Nervous system disorder—Epirubicin—breast cancer	0.000158	0.000311	CcSEcCtD
Loxapine—Dizziness—Docetaxel—breast cancer	0.000158	0.000311	CcSEcCtD
Loxapine—Thrombocytopenia—Epirubicin—breast cancer	0.000157	0.00031	CcSEcCtD
Loxapine—Hypertension—Doxorubicin—breast cancer	0.000157	0.00031	CcSEcCtD
Loxapine—Quetiapine—CYP2D6—breast cancer	0.000157	0.0142	CrCbGaD
Loxapine—Tachycardia—Epirubicin—breast cancer	0.000157	0.000309	CcSEcCtD
Loxapine—Insomnia—Methotrexate—breast cancer	0.000155	0.000306	CcSEcCtD
Loxapine—Chest pain—Doxorubicin—breast cancer	0.000155	0.000306	CcSEcCtD
Loxapine—Paraesthesia—Methotrexate—breast cancer	0.000154	0.000304	CcSEcCtD
Loxapine—Dyspnoea—Methotrexate—breast cancer	0.000153	0.000302	CcSEcCtD
Loxapine—Somnolence—Methotrexate—breast cancer	0.000153	0.000301	CcSEcCtD
Loxapine—Dizziness—Capecitabine—breast cancer	0.000153	0.000301	CcSEcCtD
Loxapine—Dry mouth—Doxorubicin—breast cancer	0.000152	0.000299	CcSEcCtD
Loxapine—Vomiting—Docetaxel—breast cancer	0.000152	0.000299	CcSEcCtD
Loxapine—Rash—Docetaxel—breast cancer	0.00015	0.000296	CcSEcCtD
Loxapine—Hypotension—Epirubicin—breast cancer	0.00015	0.000296	CcSEcCtD
Loxapine—Dermatitis—Docetaxel—breast cancer	0.00015	0.000296	CcSEcCtD
Loxapine—Confusional state—Doxorubicin—breast cancer	0.00015	0.000296	CcSEcCtD
Loxapine—Headache—Docetaxel—breast cancer	0.000149	0.000294	CcSEcCtD
Loxapine—Oedema—Doxorubicin—breast cancer	0.000149	0.000293	CcSEcCtD
Loxapine—Gastrointestinal disorder—Methotrexate—breast cancer	0.000148	0.000292	CcSEcCtD
Loxapine—Fatigue—Methotrexate—breast cancer	0.000148	0.000292	CcSEcCtD
Loxapine—Vomiting—Capecitabine—breast cancer	0.000147	0.000289	CcSEcCtD
Loxapine—Shock—Doxorubicin—breast cancer	0.000146	0.000289	CcSEcCtD
Loxapine—Nervous system disorder—Doxorubicin—breast cancer	0.000146	0.000288	CcSEcCtD
Loxapine—Thrombocytopenia—Doxorubicin—breast cancer	0.000146	0.000287	CcSEcCtD
Loxapine—Rash—Capecitabine—breast cancer	0.000146	0.000287	CcSEcCtD
Loxapine—Insomnia—Epirubicin—breast cancer	0.000145	0.000287	CcSEcCtD
Loxapine—Dermatitis—Capecitabine—breast cancer	0.000145	0.000287	CcSEcCtD
Loxapine—Tachycardia—Doxorubicin—breast cancer	0.000145	0.000286	CcSEcCtD
Loxapine—Headache—Capecitabine—breast cancer	0.000145	0.000285	CcSEcCtD
Loxapine—Paraesthesia—Epirubicin—breast cancer	0.000144	0.000285	CcSEcCtD
Loxapine—Dyspnoea—Epirubicin—breast cancer	0.000143	0.000283	CcSEcCtD
Loxapine—Somnolence—Epirubicin—breast cancer	0.000143	0.000282	CcSEcCtD
Loxapine—Nausea—Docetaxel—breast cancer	0.000142	0.000279	CcSEcCtD
Loxapine—Feeling abnormal—Methotrexate—breast cancer	0.000142	0.000279	CcSEcCtD
Loxapine—Temazepam—CYP3A4—breast cancer	0.000141	0.0127	CrCbGaD
Loxapine—Hypotension—Doxorubicin—breast cancer	0.000139	0.000274	CcSEcCtD
Loxapine—Gastrointestinal disorder—Epirubicin—breast cancer	0.000139	0.000274	CcSEcCtD
Loxapine—Fatigue—Epirubicin—breast cancer	0.000139	0.000273	CcSEcCtD
Loxapine—Constipation—Epirubicin—breast cancer	0.000138	0.000271	CcSEcCtD
Loxapine—Nausea—Capecitabine—breast cancer	0.000137	0.00027	CcSEcCtD
Loxapine—Clozapine—CYP2D6—breast cancer	0.000135	0.0122	CrCbGaD
Loxapine—Quetiapine—CYP3A4—breast cancer	0.000135	0.0121	CrCbGaD
Loxapine—Insomnia—Doxorubicin—breast cancer	0.000135	0.000265	CcSEcCtD
Loxapine—Paraesthesia—Doxorubicin—breast cancer	0.000134	0.000263	CcSEcCtD
Loxapine—Dyspnoea—Doxorubicin—breast cancer	0.000133	0.000261	CcSEcCtD
Loxapine—Feeling abnormal—Epirubicin—breast cancer	0.000133	0.000261	CcSEcCtD
Loxapine—Somnolence—Doxorubicin—breast cancer	0.000132	0.000261	CcSEcCtD
Loxapine—Gastrointestinal disorder—Doxorubicin—breast cancer	0.000128	0.000253	CcSEcCtD
Loxapine—Fatigue—Doxorubicin—breast cancer	0.000128	0.000253	CcSEcCtD
Loxapine—Constipation—Doxorubicin—breast cancer	0.000127	0.000251	CcSEcCtD
Loxapine—Hypersensitivity—Methotrexate—breast cancer	0.000127	0.00025	CcSEcCtD
Loxapine—Asthenia—Methotrexate—breast cancer	0.000123	0.000243	CcSEcCtD
Loxapine—Feeling abnormal—Doxorubicin—breast cancer	0.000123	0.000242	CcSEcCtD
Loxapine—Pruritus—Methotrexate—breast cancer	0.000122	0.00024	CcSEcCtD
Loxapine—Hypersensitivity—Epirubicin—breast cancer	0.000119	0.000234	CcSEcCtD
Loxapine—Diazepam—CYP3A4—breast cancer	0.000117	0.0106	CrCbGaD
Loxapine—Clozapine—CYP3A4—breast cancer	0.000116	0.0104	CrCbGaD
Loxapine—Trifluoperazine—ABCB1—breast cancer	0.000116	0.0104	CrCbGaD
Loxapine—Asthenia—Epirubicin—breast cancer	0.000115	0.000227	CcSEcCtD
Loxapine—Pruritus—Epirubicin—breast cancer	0.000114	0.000224	CcSEcCtD
Loxapine—Dizziness—Methotrexate—breast cancer	0.000114	0.000224	CcSEcCtD
Loxapine—Quetiapine—ABCB1—breast cancer	0.000112	0.0101	CrCbGaD
Loxapine—Hypersensitivity—Doxorubicin—breast cancer	0.00011	0.000216	CcSEcCtD
Loxapine—Vomiting—Methotrexate—breast cancer	0.000109	0.000215	CcSEcCtD
Loxapine—Rash—Methotrexate—breast cancer	0.000108	0.000214	CcSEcCtD
Loxapine—Dermatitis—Methotrexate—breast cancer	0.000108	0.000213	CcSEcCtD
Loxapine—Headache—Methotrexate—breast cancer	0.000108	0.000212	CcSEcCtD
Loxapine—Asthenia—Doxorubicin—breast cancer	0.000107	0.00021	CcSEcCtD
Loxapine—Dizziness—Epirubicin—breast cancer	0.000106	0.00021	CcSEcCtD
Loxapine—Pruritus—Doxorubicin—breast cancer	0.000105	0.000208	CcSEcCtD
Loxapine—Diazepam—ALB—breast cancer	0.000102	0.00923	CrCbGaD
Loxapine—Vomiting—Epirubicin—breast cancer	0.000102	0.000202	CcSEcCtD
Loxapine—Nausea—Methotrexate—breast cancer	0.000102	0.000201	CcSEcCtD
Loxapine—Rash—Epirubicin—breast cancer	0.000101	0.0002	CcSEcCtD
Loxapine—Dermatitis—Epirubicin—breast cancer	0.000101	0.0002	CcSEcCtD
Loxapine—Headache—Epirubicin—breast cancer	0.000101	0.000199	CcSEcCtD
Loxapine—Dizziness—Doxorubicin—breast cancer	9.84e-05	0.000194	CcSEcCtD
Loxapine—Diazepam—ABCB1—breast cancer	9.77e-05	0.00881	CrCbGaD
Loxapine—Clozapine—ABCB1—breast cancer	9.65e-05	0.0087	CrCbGaD
Loxapine—Nausea—Epirubicin—breast cancer	9.55e-05	0.000188	CcSEcCtD
Loxapine—Vomiting—Doxorubicin—breast cancer	9.46e-05	0.000186	CcSEcCtD
Loxapine—Rash—Doxorubicin—breast cancer	9.38e-05	0.000185	CcSEcCtD
Loxapine—Dermatitis—Doxorubicin—breast cancer	9.38e-05	0.000185	CcSEcCtD
Loxapine—Headache—Doxorubicin—breast cancer	9.32e-05	0.000184	CcSEcCtD
Loxapine—Nausea—Doxorubicin—breast cancer	8.84e-05	0.000174	CcSEcCtD
Loxapine—CHRM2—Signaling Pathways—CTNNB1—breast cancer	4.01e-06	9.96e-06	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—TP53—breast cancer	4.01e-06	9.95e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MMP9—breast cancer	4.01e-06	9.94e-06	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—MYC—breast cancer	4.01e-06	9.94e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—HRAS—breast cancer	4e-06	9.93e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CTNNB1—breast cancer	4e-06	9.93e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MMP9—breast cancer	4e-06	9.92e-06	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—TGFB1—breast cancer	4e-06	9.91e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CDKN1A—breast cancer	3.99e-06	9.9e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—STAT3—breast cancer	3.99e-06	9.9e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MMP9—breast cancer	3.99e-06	9.89e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CDKN1A—breast cancer	3.98e-06	9.88e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—PTEN—breast cancer	3.98e-06	9.88e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—PTEN—breast cancer	3.97e-06	9.86e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MMP9—breast cancer	3.97e-06	9.86e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CDKN1A—breast cancer	3.97e-06	9.85e-06	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—PIK3CA—breast cancer	3.97e-06	9.85e-06	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—MYC—breast cancer	3.97e-06	9.85e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—VEGFA—breast cancer	3.97e-06	9.84e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—PTEN—breast cancer	3.96e-06	9.83e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MAPK8—breast cancer	3.96e-06	9.83e-06	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—TGFB1—breast cancer	3.96e-06	9.82e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CDKN1A—breast cancer	3.96e-06	9.82e-06	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—HRAS—breast cancer	3.95e-06	9.8e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—AKT1—breast cancer	3.95e-06	9.8e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—PTEN—breast cancer	3.95e-06	9.8e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MAPK3—breast cancer	3.94e-06	9.77e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CDKN1B—breast cancer	3.94e-06	9.76e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MMP9—breast cancer	3.93e-06	9.76e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—STAT3—breast cancer	3.93e-06	9.74e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MMP9—breast cancer	3.92e-06	9.73e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CDKN1A—breast cancer	3.92e-06	9.72e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MAPK3—breast cancer	3.92e-06	9.72e-06	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—EGFR—breast cancer	3.92e-06	9.72e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—PTEN—breast cancer	3.91e-06	9.7e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CDKN1A—breast cancer	3.91e-06	9.7e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—PTEN—breast cancer	3.9e-06	9.68e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MAPK8—breast cancer	3.9e-06	9.67e-06	CbGpPWpGaD
Loxapine—ADRA2A—GPCR downstream signaling—AKT1—breast cancer	3.89e-06	9.66e-06	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—IL6—breast cancer	3.89e-06	9.65e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MAPK8—breast cancer	3.89e-06	9.65e-06	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—HRAS—breast cancer	3.89e-06	9.64e-06	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—IL6—breast cancer	3.89e-06	9.64e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—AKT1—breast cancer	3.89e-06	9.64e-06	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—EGFR—breast cancer	3.88e-06	9.63e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—AKT1—breast cancer	3.88e-06	9.62e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MAPK8—breast cancer	3.88e-06	9.62e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—AKT1—breast cancer	3.87e-06	9.59e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MAPK8—breast cancer	3.86e-06	9.58e-06	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—IL6—breast cancer	3.86e-06	9.58e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CASP3—breast cancer	3.86e-06	9.57e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—AKT1—breast cancer	3.85e-06	9.56e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL2—breast cancer	3.85e-06	9.56e-06	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—TP53—breast cancer	3.84e-06	9.53e-06	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—HRAS—breast cancer	3.84e-06	9.51e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—IL6—breast cancer	3.83e-06	9.51e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MYC—breast cancer	3.83e-06	9.51e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MAPK8—breast cancer	3.83e-06	9.49e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—TGFB1—breast cancer	3.82e-06	9.48e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—AKT1—breast cancer	3.82e-06	9.47e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MAPK8—breast cancer	3.82e-06	9.47e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MAPK3—breast cancer	3.81e-06	9.46e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MYC—breast cancer	3.81e-06	9.46e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—AKT1—breast cancer	3.81e-06	9.44e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—TGFB1—breast cancer	3.8e-06	9.43e-06	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—PIK3CA—breast cancer	3.78e-06	9.38e-06	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—IL6—breast cancer	3.78e-06	9.38e-06	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—PIK3CA—breast cancer	3.76e-06	9.34e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CCND1—breast cancer	3.75e-06	9.31e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—SRC—breast cancer	3.75e-06	9.31e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MAPK3—breast cancer	3.75e-06	9.31e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—EGFR—breast cancer	3.75e-06	9.3e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—JUN—breast cancer	3.75e-06	9.3e-06	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—PIK3CA—breast cancer	3.73e-06	9.26e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—EGFR—breast cancer	3.73e-06	9.25e-06	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—IL6—breast cancer	3.72e-06	9.23e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CTNNB1—breast cancer	3.72e-06	9.22e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MYC—breast cancer	3.71e-06	9.2e-06	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—KRAS—breast cancer	3.7e-06	9.18e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—TGFB1—breast cancer	3.7e-06	9.18e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—SRC—breast cancer	3.69e-06	9.16e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—SRC—breast cancer	3.69e-06	9.14e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—SRC—breast cancer	3.67e-06	9.12e-06	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—HRAS—breast cancer	3.67e-06	9.11e-06	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—IL6—breast cancer	3.67e-06	9.11e-06	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—KRAS—breast cancer	3.67e-06	9.1e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—SRC—breast cancer	3.66e-06	9.09e-06	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—TP53—breast cancer	3.66e-06	9.08e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—VEGFA—breast cancer	3.66e-06	9.07e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MYC—breast cancer	3.65e-06	9.05e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MMP9—breast cancer	3.65e-06	9.04e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—TGFB1—breast cancer	3.64e-06	9.03e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CDKN1A—breast cancer	3.63e-06	9.01e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—SRC—breast cancer	3.63e-06	9e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—EGFR—breast cancer	3.63e-06	9e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—PTEN—breast cancer	3.62e-06	8.99e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—STAT3—breast cancer	3.62e-06	8.98e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—SRC—breast cancer	3.62e-06	8.97e-06	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—TP53—breast cancer	3.61e-06	8.96e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—VEGFA—breast cancer	3.6e-06	8.93e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—VEGFA—breast cancer	3.59e-06	8.91e-06	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—AKT1—breast cancer	3.59e-06	8.91e-06	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—AKT1—breast cancer	3.59e-06	8.9e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—VEGFA—breast cancer	3.58e-06	8.88e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—EGFR—breast cancer	3.57e-06	8.85e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—VEGFA—breast cancer	3.57e-06	8.85e-06	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—AKT1—breast cancer	3.56e-06	8.84e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—STAT3—breast cancer	3.56e-06	8.84e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—STAT3—breast cancer	3.55e-06	8.82e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MAPK8—breast cancer	3.55e-06	8.8e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—STAT3—breast cancer	3.54e-06	8.79e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—KRAS—breast cancer	3.54e-06	8.78e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—AKT1—breast cancer	3.54e-06	8.77e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—VEGFA—breast cancer	3.53e-06	8.76e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—STAT3—breast cancer	3.53e-06	8.76e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—VEGFA—breast cancer	3.52e-06	8.74e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—KRAS—breast cancer	3.52e-06	8.74e-06	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—IL6—breast cancer	3.52e-06	8.72e-06	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—HRAS—breast cancer	3.5e-06	8.68e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—STAT3—breast cancer	3.5e-06	8.68e-06	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—AKT1—breast cancer	3.49e-06	8.65e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—STAT3—breast cancer	3.49e-06	8.65e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MAPK3—breast cancer	3.46e-06	8.58e-06	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—HRAS—breast cancer	3.45e-06	8.57e-06	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—AKT1—breast cancer	3.43e-06	8.52e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—KRAS—breast cancer	3.43e-06	8.5e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MAPK3—breast cancer	3.4e-06	8.44e-06	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—PIK3CA—breast cancer	3.4e-06	8.44e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MAPK3—breast cancer	3.4e-06	8.43e-06	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—AKT1—breast cancer	3.39e-06	8.4e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MAPK3—breast cancer	3.39e-06	8.4e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MAPK3—breast cancer	3.37e-06	8.37e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—KRAS—breast cancer	3.37e-06	8.36e-06	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—PIK3CA—breast cancer	3.37e-06	8.36e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MYC—breast cancer	3.36e-06	8.35e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—SRC—breast cancer	3.36e-06	8.34e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—TGFB1—breast cancer	3.36e-06	8.33e-06	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—IL6—breast cancer	3.35e-06	8.31e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MAPK3—breast cancer	3.34e-06	8.29e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MAPK3—breast cancer	3.33e-06	8.27e-06	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—PIK3CA—breast cancer	3.33e-06	8.27e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MYC—breast cancer	3.31e-06	8.21e-06	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—IL6—breast cancer	3.31e-06	8.2e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MYC—breast cancer	3.3e-06	8.19e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—TGFB1—breast cancer	3.3e-06	8.19e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—TGFB1—breast cancer	3.3e-06	8.17e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MYC—breast cancer	3.29e-06	8.17e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—EGFR—breast cancer	3.29e-06	8.16e-06	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—TP53—breast cancer	3.29e-06	8.16e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—TGFB1—breast cancer	3.28e-06	8.15e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MYC—breast cancer	3.28e-06	8.14e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—TGFB1—breast cancer	3.27e-06	8.12e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—VEGFA—breast cancer	3.27e-06	8.12e-06	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—TP53—breast cancer	3.26e-06	8.09e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—PIK3CA—breast cancer	3.25e-06	8.07e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MYC—breast cancer	3.25e-06	8.06e-06	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—AKT1—breast cancer	3.24e-06	8.05e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—TGFB1—breast cancer	3.24e-06	8.04e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MYC—breast cancer	3.24e-06	8.04e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—STAT3—breast cancer	3.24e-06	8.04e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—EGFR—breast cancer	3.24e-06	8.03e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—PIK3CA—breast cancer	3.24e-06	8.03e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—TGFB1—breast cancer	3.23e-06	8.02e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—EGFR—breast cancer	3.23e-06	8.02e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—EGFR—breast cancer	3.22e-06	7.99e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—EGFR—breast cancer	3.21e-06	7.96e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—EGFR—breast cancer	3.18e-06	7.89e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—EGFR—breast cancer	3.17e-06	7.87e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—PIK3CA—breast cancer	3.15e-06	7.81e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—TP53—breast cancer	3.15e-06	7.81e-06	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—HRAS—breast cancer	3.15e-06	7.81e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—TP53—breast cancer	3.13e-06	7.77e-06	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—HRAS—breast cancer	3.12e-06	7.73e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—KRAS—breast cancer	3.11e-06	7.71e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—PIK3CA—breast cancer	3.1e-06	7.69e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MAPK3—breast cancer	3.1e-06	7.68e-06	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—AKT1—breast cancer	3.09e-06	7.67e-06	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—AKT1—breast cancer	3.08e-06	7.63e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—KRAS—breast cancer	3.06e-06	7.59e-06	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—PIK3CA—breast cancer	3.06e-06	7.59e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—KRAS—breast cancer	3.05e-06	7.57e-06	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—AKT1—breast cancer	3.05e-06	7.56e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—TP53—breast cancer	3.05e-06	7.55e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—KRAS—breast cancer	3.04e-06	7.55e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—KRAS—breast cancer	3.03e-06	7.52e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MYC—breast cancer	3.01e-06	7.47e-06	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—IL6—breast cancer	3.01e-06	7.47e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—HRAS—breast cancer	3.01e-06	7.47e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—TGFB1—breast cancer	3e-06	7.45e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—KRAS—breast cancer	3e-06	7.45e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—TP53—breast cancer	3e-06	7.43e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—KRAS—breast cancer	3e-06	7.43e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—HRAS—breast cancer	2.99e-06	7.43e-06	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—IL6—breast cancer	2.98e-06	7.4e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—EGFR—breast cancer	2.95e-06	7.31e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—HRAS—breast cancer	2.91e-06	7.22e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—IL6—breast cancer	2.88e-06	7.15e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—HRAS—breast cancer	2.87e-06	7.11e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—IL6—breast cancer	2.87e-06	7.11e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—PIK3CA—breast cancer	2.86e-06	7.09e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—PIK3CA—breast cancer	2.81e-06	6.97e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—PIK3CA—breast cancer	2.8e-06	6.96e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—PIK3CA—breast cancer	2.8e-06	6.93e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IL6—breast cancer	2.79e-06	6.91e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—PIK3CA—breast cancer	2.79e-06	6.91e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—KRAS—breast cancer	2.78e-06	6.9e-06	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—AKT1—breast cancer	2.78e-06	6.89e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—TP53—breast cancer	2.76e-06	6.85e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—PIK3CA—breast cancer	2.76e-06	6.85e-06	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—AKT1—breast cancer	2.75e-06	6.83e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—PIK3CA—breast cancer	2.75e-06	6.83e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IL6—breast cancer	2.74e-06	6.81e-06	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—AKT1—breast cancer	2.72e-06	6.75e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—TP53—breast cancer	2.72e-06	6.74e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—TP53—breast cancer	2.71e-06	6.73e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—TP53—breast cancer	2.7e-06	6.71e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—TP53—breast cancer	2.7e-06	6.69e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—TP53—breast cancer	2.67e-06	6.62e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—TP53—breast cancer	2.66e-06	6.6e-06	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—AKT1—breast cancer	2.66e-06	6.59e-06	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—AKT1—breast cancer	2.64e-06	6.56e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—HRAS—breast cancer	2.64e-06	6.56e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—HRAS—breast cancer	2.6e-06	6.45e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—HRAS—breast cancer	2.59e-06	6.44e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—HRAS—breast cancer	2.59e-06	6.42e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—HRAS—breast cancer	2.58e-06	6.4e-06	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—AKT1—breast cancer	2.57e-06	6.38e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—PIK3CA—breast cancer	2.56e-06	6.34e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—HRAS—breast cancer	2.55e-06	6.33e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—HRAS—breast cancer	2.55e-06	6.32e-06	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—AKT1—breast cancer	2.53e-06	6.28e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IL6—breast cancer	2.53e-06	6.27e-06	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—AKT1—breast cancer	2.5e-06	6.2e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IL6—breast cancer	2.49e-06	6.17e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IL6—breast cancer	2.48e-06	6.16e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IL6—breast cancer	2.48e-06	6.14e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—TP53—breast cancer	2.47e-06	6.14e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IL6—breast cancer	2.47e-06	6.12e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IL6—breast cancer	2.44e-06	6.06e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IL6—breast cancer	2.44e-06	6.04e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—HRAS—breast cancer	2.37e-06	5.87e-06	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—AKT1—breast cancer	2.33e-06	5.79e-06	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—AKT1—breast cancer	2.3e-06	5.7e-06	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—AKT1—breast cancer	2.29e-06	5.68e-06	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—AKT1—breast cancer	2.28e-06	5.66e-06	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—AKT1—breast cancer	2.28e-06	5.65e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL6—breast cancer	2.26e-06	5.62e-06	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—AKT1—breast cancer	2.25e-06	5.59e-06	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—AKT1—breast cancer	2.25e-06	5.58e-06	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—AKT1—breast cancer	2.09e-06	5.18e-06	CbGpPWpGaD
